---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-26-000008"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2026-01-15T23:59:59+00:00"
generated_at: "2026-05-16T10:05:13.041668+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio reports preliminary FY2025 ANKTIVA revenue ~$113M, up ~700% YoY, and Saudi approval for NSCLC

## Summary
- Preliminary FY2025 net product revenue ~$113.0M, ~700% YoY increase; Q4 2025 revenue ~$38.3M, up 20% QoQ and 431% YoY.
- ANKTIVA unit sales volume grew 750% in 2025 vs 2024; quarter-over-quarter unit growth 54% during FY2025.
- Saudi FDA approved ANKTIVA + checkpoint inhibitor for metastatic NSCLC (first global approval for this indication) and + BCG for NMIBC CIS.
- Phase 2b QUILT-2.005 trial enrollment ahead of expectations; full enrollment anticipated in H1 2026.
- Estimated cash, cash equivalents and marketable securities of $242.8M as of Dec 31, 2025.

## SEC filing metadata
- accession: 0001326110-26-000008
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2026-01-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/0001326110-26-000008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000008/ibrx-20260115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-26-000008
- JSON: https://secwatch.observer/filing/0001326110-26-000008.json
- Plain text: https://secwatch.observer/filing/0001326110-26-000008.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.